RE: TS -21 Apr 2026 07:06
Matthew Moulding, CEO of THG commented:
"It is energising for everyone at THG to see such a strong start to 2026, building on the better-than-expected momentum we delivered in H2 2025.
In Beauty, Lookfantastic is once again outperforming the market following two years of business model change, while the US continues to perform strongly.
In Nutrition, our diversification into margin-accretive categories is now clearly paying dividends. Activewear continues to deliver exceptional growth, with annualised run-rate sales fast approaching £100m. Growth across activewear and other high-margin categories, including creatine, hydration and collagen, is helping to offset record whey commodity pricing.
While the geopolitical backdrop remains uncertain, we enter Q2 with confidence after a better-than-expected Q1, giving us a stronger base against any unforeseen risks later in the year."
THG Beauty Q1 2026 highlights
●
THG Beauty entered 2026 with significant momentum in UK and US retail. In the UK, orders grew by 7% alongside growth in the LTM active customer base.
●
US retail saw revenue growth and market share expansion[5], driven by a 10% increase in new customers. Dermstore became one of the first major online beauty retailers to partner with Flex, enabling customers to pay for a significantly greater amount of their skincare regime with their pre-tax earnings through Health Savings (HSA) and Flexible Spending (FSA) accounts directly at checkout, improving affordability and convenience whilst supporting AOV increases.
●
The K-Beauty category was a standout performer, with revenue more than doubling YoY, supported by the launch of six new brands YTD. Across the platform, new brand launches continued to support growth with SkinCeuticals and MAC exceeding expectations since their launch on Cult Beauty.
●
The new Lookfantastic store in Bristol is outperforming the initial flagship store launch, creating a localised halo effect supporting brand awareness and new customer acquisition.
●
The own-brand portfolio is building on the lifecycle investments made in 2025, securing new retail and spa listings for Ameliorate and ESPA. Within manufacturing, revenue growth is driven by strategic new business wins alongside continued growth from its existing customer base.